LNTH-2403 / Lantheus - LARVOL DELTA

Mass dose effects of the immunotheranostic [89Zr]Zr-LNTH-2403 by PET/CT and dosimetry in non-human primates (AACR 2026) - "These findings demonstrate a favorable safety and dosimetry profile for [89Zr] Zr-LNTH-2403 in NHPs, supporting its advancement toward first-in-human imaging studies. Importantly, the administered mass of mAb significantly affected the radiotracer's blood and normal organ biodistribution, highlighting the value of preclinical mass-dose optimization in humans."

First-in-human • Oncology • Solid Tumor • LRRC1

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) (clinicaltrials.gov) - P1/2 | N=55 | Recruiting | Sponsor: Lantheus Medical Imaging | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) (clinicaltrials.gov) - P1/2 | N=55 | Not yet recruiting | Sponsor: Lantheus Medical Imaging

New P1/2 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

DUNP19: A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=16 | Not yet recruiting | Sponsor: Radiopharm Theranostics, Ltd

New P1 trial • Breast Cancer • Colorectal Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer